@article{0dfa9cf919fc4f2c9edc2019774d2216,
title = "Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance)",
abstract = "Peripheral neuropathy is a common dose-limiting toxicity for patients treated with paclitaxel. For most individuals, there are no known risk factors that predispose patients to the adverse event, and pathogenesis for paclitaxel-induced peripheral neuropathy is unknown. Determining whether there is a heritable component to paclitaxel-induced peripheral neuropathy would be valuable in guiding clinical decisions and may provide insight into treatment of and mechanisms for the toxicity. Using genotype and patient information from the paclitaxel arm of CALGB 40101 (Alliance), a phase III clinical trial evaluating adjuvant therapies for breast cancer in women, we estimated the variance in maximum grade and dose at first instance of sensory peripheral neuropathy. Our results suggest that paclitaxel-induced neuropathy has a heritable component, driven in part by genes involved in axon outgrowth. Disruption of axon outgrowth may be one of the mechanisms by which paclitaxel treatment results in sensory peripheral neuropathy in susceptible patients.",
author = "A. Chhibber and J. Mefford and Stahl, {E. A.} and Pendergrass, {S. A.} and Baldwin, {R. M.} and K. Owzar and M. Li and Winer, {E. P.} and Hudis, {C. A.} and H. Zembutsu and M. Kubo and Y. Nakamura and McLeod, {H. L.} and Ratain, {M. J.} and Shulman, {L. N.} and Ritchie, {M. D.} and Plenge, {R. M.} and Witte, {J. S.} and Kroetz, {D. L.}",
note = "Funding Information: The research for CALGB 60202 and 40101 was supported, in part, by grants from the National Cancer Institute (CA31946) to the Alliance for Clinical Trials in Oncology (Monica M Bertagnolli, MD, Chair) and to the Alliance Statistics and Data Center (Daniel J Sargent, PhD, CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. This work was also supported, in part, by the NIH Grants U01 GM61390, U01 GM61393 and U01 HL065962 and the Biobank Japan Project funded by the Japanese Ministry of Education, Culture, Sports, Science and Technology. The genotyping used for this work was generated as part of the NIH Pharmacogenomics Research Network-RIKEN Center for Genomic Medicine Global Alliance. AC and ML were supported, in part, by the NIH Training Grant T32 GM007175.",
year = "2014",
month = aug,
doi = "10.1038/tpj.2014.2",
language = "English (US)",
volume = "14",
pages = "336--342",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Springer Nature",
number = "4",
}